A study on clinical effectiveness of cosmetics containing human stem cell conditioned media

Abstract

Abstract Background With the steadily increasing trend of functional cosmetics consumption, the public is increasingly expecting the efficacy of cosmetics, and in order to meet these consumer needs, the development of various effective raw materials, as well as products through technical convergence research, has been activating focusing on dermatology. In the Republic of Korea, much attention was paid to cosmetic raw materials using human stem cells as a new growth engine at the end of the 2000s. Accordingly, the Ministry of Food and Drug Safety implemented the Regulations on Cosmetic Safety Standards, etc., which contains the safety standards of human-derived cell and tissue culture as raw materials for cosmetics. Methods Twice a day, morning and evening, for 28 days, 3 mL of the sample provided for each subject was applied onto the entire face using an airbrush. The subjects were divided into a control group (C), an experimental group 1 (ADSC-CM 5% group, E1) and an experimental group 2 (polymersome-containing of ADSC-CM 5% group, E2), and there were 20 subjects in each group. Results Moisture content on the U-zone, melanin and erythema of lid-cheek, overall size and depth of eye wrinkles, and skin roughness of the items showed significant differences among all three groups. More specifically, E1 had a higher rate of skin improvement than C, and E2 had the highest skin improvement rate in all items: skin moisture content, transepidermal water loss (TEWL), melanin and erythema of lid-cheek, eye wrinkles, and skin roughness of lid-cheek. Conclusions The effectiveness of ADSC-CM was verified in all items: increases in moisture content, decrease in TEWL, and improvements of whitening and wrinkles. Moreover, the effectiveness of ADSC-CM was observed as higher in samples of polymersome-containing ADSC-CM than those of raw material ADSC-CM. Furthermore, percutaneous absorption was improved compared with previous studies on formulations in relation to polymersome at the same concentration of ADSC-CM, thereby resulting in higher effectiveness. Trial registration Korea National Institute for Bioethics Policy, P01–201809–13-001, Registered 06 September 2018, http://public.irb.or.kr/.